Puroxan helps relieve dry cough and aids in clearing the respiratory tract.
Pulmonology → Broncholytic agents → Phosphodiesterase inhibitors
• 24-hour control of COPD and asthma
• Wide therapeutic window: well tolerated
• Fast and effective bronchodilation (4)
• Safe for patients with heart disease (9)
• Improves patient adherence
• No dose adjustment needed for elderly patients
• Can be prescribed together with:
Anti-leukotrienes
Corticosteroids
Mucolytic agents
Doxofylline
Each modified-release tablet contains 650 mg of doxofylline.
Puruxan-Top is indicated for the treatment of chronic respiratory diseases such as bronchial asthma and chronic obstructive pulmonary disease (COPD).
One tablet once daily, preferably in the evening with a glass of water, or as directed by a physician.
This product is contraindicated in individuals with hypersensitivity to any of its components.
It is also contraindicated in patients with acute myocardial infarction, hypotension, and in breastfeeding women.
Although significant arrhythmias have not been reported with doxofylline, overdose of xanthine derivatives may cause severe cardiac rhythm disturbances.
If a potential oral overdose of Puruxan-Top is identified, seizures may occur; these may be the first signs of intoxication.
Adverse reactions may require discontinuation of treatment.
Reinitiation at a lower dose is possible only upon physician advice.
No specific antidote exists; management principles should follow symptomatic treatment of cardiocirculatory shock.
After administration of xanthines, the following may occur: nausea, vomiting, epigastric pain, headache, irritability, insomnia, tachycardia, extrasystole, tachypnea, and rarely hyperglycemia and albuminuria.
In case of oral overdose, severe arrhythmia and seizures may occur — possible early signs of intoxication.
Adverse reactions may require discontinuation of therapy; restarting at a lower dose is possible only with medical advice.
